Deoxyribonucleic acid damage-associated biomarkers of ionising radiation
Standard
Deoxyribonucleic acid damage-associated biomarkers of ionising radiation : current status and future relevance for radiology and radiotherapy. / Manning, G; Rothkamm, K.
in: BRIT J RADIOL, Jahrgang 86, Nr. 1027, 07.2013, S. 20130173.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Deoxyribonucleic acid damage-associated biomarkers of ionising radiation
T2 - current status and future relevance for radiology and radiotherapy
AU - Manning, G
AU - Rothkamm, K
PY - 2013/7
Y1 - 2013/7
N2 - Diagnostic and therapeutic radiation technology has developed dramatically in recent years, and its use has increased significantly, bringing clinical benefit. The use of diagnostic radiology has become widespread in modern society, particularly in paediatrics where the clinical benefit needs to be balanced with the risk of leukaemia and brain cancer increasing after exposure to low doses of radiation. With improving long-term survival rates of radiotherapy patients and the ever-increasing use of diagnostic and interventional radiology procedures, concern has risen over the long-term risks and side effects from such treatments. Biomarker development in radiology and radiotherapy has progressed significantly in recent years to investigate the effects of such use and optimise treatment. Recent biomarker development has focused on improving the limitations of established techniques by the use of automation, increasing sensitivity and developing novel biomarkers capable of quicker results. The effect of low-dose exposure (0-100 mGy) used in radiology, which is increasingly linked to cancer incidences, is being investigated, as some recent research challenges the linear-no-threshold model. Radiotherapy biomarkers are focused on identifying radiosensitive patients, determining the treatment-associated risk and allowing for a tailored and more successful treatment of cancer patients. For biomarkers in any of these areas to be successfully developed, stringent criteria must be applied in techniques and analysis of data to reduce variation among reports and allow data sets to be accurately compared. Newly developed biomarkers can then be used in combination with the established techniques to better understand and quantify the individual biological response to exposures associated with radiology tests and to personalise treatment plans for patients.
AB - Diagnostic and therapeutic radiation technology has developed dramatically in recent years, and its use has increased significantly, bringing clinical benefit. The use of diagnostic radiology has become widespread in modern society, particularly in paediatrics where the clinical benefit needs to be balanced with the risk of leukaemia and brain cancer increasing after exposure to low doses of radiation. With improving long-term survival rates of radiotherapy patients and the ever-increasing use of diagnostic and interventional radiology procedures, concern has risen over the long-term risks and side effects from such treatments. Biomarker development in radiology and radiotherapy has progressed significantly in recent years to investigate the effects of such use and optimise treatment. Recent biomarker development has focused on improving the limitations of established techniques by the use of automation, increasing sensitivity and developing novel biomarkers capable of quicker results. The effect of low-dose exposure (0-100 mGy) used in radiology, which is increasingly linked to cancer incidences, is being investigated, as some recent research challenges the linear-no-threshold model. Radiotherapy biomarkers are focused on identifying radiosensitive patients, determining the treatment-associated risk and allowing for a tailored and more successful treatment of cancer patients. For biomarkers in any of these areas to be successfully developed, stringent criteria must be applied in techniques and analysis of data to reduce variation among reports and allow data sets to be accurately compared. Newly developed biomarkers can then be used in combination with the established techniques to better understand and quantify the individual biological response to exposures associated with radiology tests and to personalise treatment plans for patients.
KW - Biomarkers/analysis
KW - DNA/radiation effects
KW - Dose-Response Relationship, Radiation
KW - Gene Expression/radiation effects
KW - Humans
KW - In Situ Hybridization, Fluorescence
KW - Lymphocytes/radiation effects
KW - Micronucleus Tests
KW - Neoplasms, Radiation-Induced/prevention & control
KW - Radiation Oncology
KW - Radiation, Ionizing
KW - Risk Assessment
U2 - 10.1259/bjr.20130173
DO - 10.1259/bjr.20130173
M3 - SCORING: Review article
C2 - 23659923
VL - 86
SP - 20130173
JO - BRIT J RADIOL
JF - BRIT J RADIOL
SN - 0007-1285
IS - 1027
ER -